Inhibrx Biosciences CEO Increases Stake After Positive Cancer Drug Trial Results

Key Facts

1Inhibrx Biosciences CEO Mark Lappe purchased 5,895 shares at a price of $99.29 per share.

2Phase 2 HexAgon study results showed INBRX-106 combined with Keytruda achieved a 48.3% confirmed objective response rate.

3INBX stock fell 5.64% to close at $114.34 despite the positive clinical data.

In a move reflecting leadership confidence in the company's clinical trajectory despite market volatility, Inhibrx Biosciences CEO Mark Lappe purchased 5,895 shares at $99.29 per share. This insider activity followed the announcement of positive Phase 2 HexAgon study results, where the drug candidate INBRX-106, combined with Keytruda, achieved a confirmed objective response rate of 48.3%. Despite the robust clinical data, INBX stock fell 5.64% to close at $114.34, prompting the CEO to increase his total ownership to 711,443 shares.

The clinical data highlighted the efficacy of the combination therapy, which outperformed Keytruda monotherapy's 26.5% response rate and demonstrated an interim median progression-free survival of 9.6 months. Within the sector context, these results involve Keytruda, a therapy produced by Merck & Co., a pivotal partner in these head and neck cancer trials. According to market data, MRK stock closed at $150.33 on September 4, 2026, trading within a daily range of $150.09 to $152.22.

Regarding current price levels, MRK stood at $150.33 (close September 4, 2026), while investors are monitoring how INBX shares react to insider buying following the recent dip. The upcoming economic calendar does not show immediate catalysts for the biotech sector in the next few days; however, the market remains attentive to further updates regarding the regulatory path for INBRX-106 following the successful Phase 2 trial results.